Exelixis Dirección
Dirección controles de criterios 4/4
El CEO de Exelixis es Mike Morrissey , nombrado en Jul 2010, tiene una permanencia de 14.33 años. compensación anual total es $16.42M, compuesta por 7.3% salario y 92.7% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.55% de las acciones de la empresa, por valor de $54.00M. La antigüedad media del equipo directivo y de la junta directiva es de 8.5 años y 7.4 años, respectivamente.
Información clave
Mike Morrissey
Chief Executive Officer (CEO)
US$16.4m
Compensación total
| Porcentaje del salario del CEO | 7.3% |
| Permanencia del CEO | 14.3yrs |
| Participación del CEO | 0.5% |
| Permanencia media de la dirección | 8.5yrs |
| Promedio de permanencia en la Junta Directiva | 7.4yrs |
Actualizaciones recientes de la dirección
Recent updates
Exelixis: Cabometyx Drives Revenue While Zanzalintinib Emerges As Future Growth Engine
Oct 31Exelixis, Inc.'s (NASDAQ:EXEL) Shares Leap 25% Yet They're Still Not Telling The Full Story
Oct 31
Here's Why We Think Exelixis (NASDAQ:EXEL) Is Well Worth Watching
Oct 26Getting In Cheap On Exelixis, Inc. (NASDAQ:EXEL) Might Be Difficult
Sep 02Exelixis Comes Up Aces
Aug 08If EPS Growth Is Important To You, Exelixis (NASDAQ:EXEL) Presents An Opportunity
Jun 14It's Unlikely That Exelixis, Inc.'s (NASDAQ:EXEL) CEO Will See A Huge Pay Rise This Year
May 24Exelixis' (NASDAQ:EXEL) Strong Earnings Are Of Good Quality
May 07Exelixis: With Patent Litigation Decision Due Soon, There Are Options
May 02Exelixis, Inc.'s (NASDAQ:EXEL) Earnings Haven't Escaped The Attention Of Investors
Apr 22Exelixis: Patent Woes And Challenging Market Dynamics Make For A Testy 2024
Mar 28We Ran A Stock Scan For Earnings Growth And Exelixis (NASDAQ:EXEL) Passed With Ease
Feb 26Exelixis: Bullish Despite The High Stakes Game Of Cabometyx Patent Battles
Jan 17Exelixis, Inc.'s (NASDAQ:EXEL) Revenues Are Not Doing Enough For Some Investors
Dec 27An Intrinsic Calculation For Exelixis, Inc. (NASDAQ:EXEL) Suggests It's 49% Undervalued
May 30Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$467m |
| Jun 30 2024 | n/a | n/a | US$350m |
| Mar 31 2024 | n/a | n/a | US$205m |
| Dec 31 2023 | n/a | n/a | US$208m |
| Sep 30 2023 | n/a | n/a | US$92m |
| Jun 30 2023 | n/a | n/a | US$164m |
| Mar 31 2023 | n/a | n/a | US$154m |
| Dec 31 2022 | US$17m | US$1m | US$182m |
| Sep 30 2022 | n/a | n/a | US$308m |
| Jun 30 2022 | n/a | n/a | US$273m |
| Mar 31 2022 | n/a | n/a | US$298m |
| Dec 31 2021 | US$8m | US$1m | US$231m |
| Sep 30 2021 | n/a | n/a | US$164m |
| Jun 30 2021 | n/a | n/a | US$94m |
| Mar 31 2021 | n/a | n/a | US$65m |
| Dec 31 2020 | n/a | n/a | US$112m |
| Sep 30 2020 | n/a | n/a | US$152m |
| Jun 30 2020 | n/a | n/a | US$282m |
| Mar 31 2020 | n/a | n/a | US$294m |
| Dec 31 2019 | n/a | n/a | US$321m |
| Sep 30 2019 | n/a | n/a | US$612m |
| Jun 30 2019 | n/a | n/a | US$642m |
| Mar 31 2019 | n/a | n/a | US$650m |
| Dec 31 2018 | n/a | n/a | US$690m |
| Sep 30 2018 | n/a | n/a | US$368m |
| Jun 30 2018 | n/a | n/a | US$323m |
| Mar 31 2018 | n/a | n/a | US$253m |
| Dec 31 2017 | n/a | n/a | US$154m |
Compensación vs. Mercado: La compensación total ($USD16.42M) de Mike está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD12.73M).
Compensación vs. Ingresos: La compensación de Mike ha sido consistente con los resultados de la empresa en el último año.
CEO
Mike Morrissey (63 yo)
14.3yrs
Permanencia
US$16,423,307
Compensación
Dr. Michael M. Morrissey, Ph.D. also known as Mike, serves as Independent Director at XW Laboratories Inc. Dr. Morrissey serves as Independent Chairman of the Board at Vera Therapeutics, Inc since May 24,...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder & Chair of the Board | 29.9yrs | US$519.97k | 0.43% $ 43.0m | |
| CEO, President & Director | 14.3yrs | US$16.42m | 0.55% $ 54.0m | |
| Executive VP & CFO | 9.3yrs | US$4.95m | 0.16% $ 15.6m | |
| Executive VP of Discovery and Translational Research & Chief Scientific Officer | 1.9yrs | US$5.65m | 0.076% $ 7.5m | |
| Executive VP & General Counsel | 10.8yrs | US$4.56m | 0.10% $ 10.2m | |
| Executive VP | 1.3yrs | US$7.38m | sin datos | |
| Executive Vice President of Public Affairs & Investor Relations | 7.9yrs | sin datos | sin datos | |
| Senior Vice President of Human Resources | less than a year | sin datos | sin datos | |
| Senior Vice President of Drug Safety | 9.6yrs | sin datos | sin datos | |
| Senior Vice President of Medical Affairs | 9.2yrs | sin datos | sin datos | |
| Executive Vice President of Commercial | 7.9yrs | US$4.65m | 0.049% $ 4.8m | |
| VP & Head of Business Development | no data | sin datos | sin datos |
8.5yrs
Permanencia media
57yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de EXEL es experimentado (8.5 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder & Chair of the Board | 29.9yrs | US$519.97k | 0.43% $ 43.0m | |
| CEO, President & Director | 14.3yrs | US$16.42m | 0.55% $ 54.0m | |
| Independent Director | 20.8yrs | US$490.97k | 0.12% $ 11.5m | |
| Independent Director | 20.3yrs | US$482.22k | 0.053% $ 5.2m | |
| Member of the Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of the Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | less than a year | sin datos | 0% $ 0 | |
| Independent Director | less than a year | sin datos | 0% $ 0 | |
| Independent Director | 8.2yrs | US$490.92k | 0.00027% $ 26.7k | |
| Independent Director | 6.6yrs | US$488.72k | 0.025% $ 2.5m | |
| Independent Director | 1.5yrs | US$717.44k | 0.0016% $ 157.3k | |
| Independent Director | 1.5yrs | US$716.19k | 0.0016% $ 157.3k |
7.4yrs
Permanencia media
68yo
Promedio de edad
Junta con experiencia: La junta directiva de EXEL se considera experimentada (7.4 años de antigüedad promedio).